Tumor mutational burden (TMB) was studied in the KEYNOTE-061 study as a biomarker beyond PD-L1 expression and predicted efficiency of Pembrolizumab treatment [61,63] even when patients with MSI were excluded [63]. This evidence concerns the gene CD274 and neoplasm.